Rotarix reduces resource use and healthcare costs in USA

Rotarix reduces resource use and healthcare costs in USA PharmacoEconomics & Outcomes News 784, p26 - 12 Aug 2017 Rotarix reduces resource use and healthcare costs in USA GlaxoSmithKline’s (GSK’s) rotavirus vaccine, Rotarix [RIX 44414; RV1], reduces rotavirus (RV)- and diarrhoea-related resource use and healthcare costs in the US, according to findings of a GSK-funded study published in Vaccine. Data from Truven Commercial Claims and Encounters Databases were used to evaluate the public health impact of Rotarix vaccination in 225 587 commercially- insured children born between 2007 and 2010 and followed until up to five years of age. In total, 34 928 infants received complete vaccination (two doses), 8390 infants received incomplete vaccination (one dose), and 182 269 were unvaccinated. Compared with the unvaccinated cohort, the incidence of first episodes of rotavirus was significantly lower in the cohort who received complete vaccination (incidence rate ratio [IRR] 0.17; 95% CI 0.09, 0.30) or incomplete vaccination (IRR 0.19; 95% CI 0.06, 0.58). Rates of rotavirus-related inpatient, outpatient and emergency room (ER) visits, and diarrhoea-related inpatient and ER visits, were significantly lower in the cohort who received complete vaccination than in the unvaccinated cohort. Rates of rotavirus-related inpatient and ER visits were also significantly lower in the partially vaccinated cohort. The adjusted mean cost for first rotavirus episode was reduced by $11 511 per 1000 patients in the completely vaccinated cohort compared with the unvaccinated cohort, and the adjusted mean cost for first diarrhoea episode was reduced by $46 772 per 1000 patients. "Given the effectiveness of RV1 vaccination and RV vaccination in general, efforts should focus on improving RV vaccination rates which lag behind most pediatric vaccination rates and continue to fall below the Healthy People 2020 target of 80%," commented the authors. * 2012 US dollars Krishnarajah G, et al. Public health impact of Rotarix vaccination among commercially insured children in the United States. Vaccine : Aug 2017. Available from: URL: 803263873 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 PharmacoEconomics & Outcomes News Springer Journals

Rotarix reduces resource use and healthcare costs in USA

1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial